



Meda acquires additional OTC products in the US from GSK

Meda has acquired two additional and well established Over-The-Counter consumer products in the US from GlaxoSmithKline LLC ("GSK"). During December 2010, Meda acquired three other OTC products from GSK.

Total annual sales for the two newly acquired products are about 80 MSEK, with strong profit margins. The purchase price was about 180 MSEK.

"By adding these two well known consumer brands, we continue to develop our US OTC presence", said Anders Lönner, CEO Meda.

For questions, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878

MEDA AB (publ) is a leading international specialty pharma company. Meda's products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.